

3/2023

Ustekinumab (STELARA) INDUCTION Infusion only

NAME: **INSURANCE:** PROVIDER NAME: **CLINIC NAME and Phone number:**

Patient identification

weignt:	kg Height:cm Aliergies: Diagnosis Code:
Treatme	t Start Date:
If trea	ment not started within 90 days, new orders with updated date/signature will be required.
GUIDEL	ES FOR ORDERING:
1)	atient <u>name and date of birth</u> must be on EACH page of this order form. This form will be returned if an
	eft blank.
2)	end FACE SHEET and complete copy of INSURANCE information. Send H&P or most recent chart note,
	nust be within the past 12 months.
3)	end a copy of related lab results if not available for review in Epic.
REQUIR	Pre-screening labs: (Results must be available prior to initiation of therapy, attach copy if not available
in Epic)	
\checkmark	QuantiFERON Gold TB (must be resulted prior to initiation of therapy).
Recomn	ended Pre-screening labs: Send any applicable results from list below.
•	BC
•	CMP
Optiona	LABS to be done at infusion appointment: (select all that apply)
	Comprehensive Metabolic Set, Routine, once.
	BC with differential, Routine, once.
	Other:
	ON: ***OPI only provides initial induction infusion, NOT maintenance doses. ***
\checkmark	ISTEKINUMAB (STELARA) in 250 ml 0.9% normal saline IVPB, iv, infuse over 1 hour. Use 0.2 micron filter
	or administration. Do not infuse concomitantly in the same IV line with other agents. After infusion
	omplete, patient to follow up with provider for maintenance doses.
•	ust select only one)
	60 mg, one time dose. For patients less than 55 kg.
	90 mg, one time dose. For patients greater than 55 kg and less than 85 kg.
	20 mg, one time dose. For patients greater than 85 kg.
AS NEE	D MEDICATIONS:
\checkmark	odium chloride 0.9% (NS) bolus 250 ml, Flush before and after IV medication(s) and as needed with NS.

✓ Vital signs: Monitor and record vital signs, tolerance, and presence of infusion-related reactions prior to

✓ If hypersensitivity or infusion reactions develop, temporarily hold the infusion, and notify provider

HYPERSENSITIVITY INFUSION REACTION ORDERS

infusion and at the end of infusion. ✓ Insert peripheral IV if no iv access.

Standard included Nursing Orders:

STOP infusion if:

MILD REACTION: Localized pruritus, rhinitis, localized rash, fever greater than 38 degrees C.

✓ May use/access CVC line and give 500 units (5ml) heparin injection for central line care.

immediately. Include hypersensitivity reaction order set. (See attached form).

- 1. Stop infusion and maintain IV access with NS line.
- 2. Notify MD of symptoms and infusion reaction orders initiated.



Ustekinumab (STELARA) INDUCTION Infusion only

NAME:
BIRTHDATE:
INSURANCE:
PROVIDER NAME:
CLINIC NAME and Phone number:

Patient identification

MODERATE REACTION: Generalized pruritus, generalized flushing, rash, back pain, mild dyspnea, chills, hypotension with SBP less than 90 mmHg or greater than 20% decrease in SBP.

- 1. Stop infusion, but do not discard infusion bag/bottle unless instructed by MD that therapy is to be discontinued.
 - 2. Maintain IV access with NS line.
 - 3. Place patients in a supine position with lower extremities elevated unless respiratory distress or nausea/vomiting.
 - 4. Maintain airway.

SEVERE REACTION: Respiratory distress (bronchospasm, stridor, wheezing, persistent cough, respiratory depression, cardiac arrhythmia, chest pain, generalized urticaria (hives), syncope, gastrointestinal symptoms (abdominal pain, N/V, diarrhea), hypotension SBP less than 80 mmHg, face/throat/tongue swelling, shock, loss of consciousness.

- 1. Stop infusion, but do not discard bag/bottle unless instructed by MD that therapy is to be discontinued.
- 2. Stay with patient and have another nurse notify MD of symptoms and infusion reaction orders initiated
- 3. Place patients in supine position with lower extremities elevated unless respiratory distress or nausea/vomiting.
- 4. Maintain airway.
- 5. Maintain IV access with NS line.
- 6. Inpatients: Activate code blue for loss of blood pressure, pulse, or consciousness.

MEDICATIONS:

- Acetaminophen (TYLENOL) tablet 650 mg, Oral, EVERY 4 HOURS PRN, Pain, Other, Mild reaction. Starting when released.
- DiphenhydrAMINE (Benadryl) injection, 25 mg, Intravenous, EVERY 15 MIN PRN, Moderate or severe reaction, may repeat x1. Starting when released, For 2 doses.
- Methylprednisolone sodium succinate (solu-MEDROL) 62.5mg/ml injection, 125 mg, Intravenous, ONCE PRN, Severe reaction. Starting when released, For 1 dose. Mix with 2 mL provided diluent to make 62.5 mg/mL.
- Famotidine (PEPCID) injection 20 mg, Intravenous, ONCE PRN, Moderate reaction, or anaphylaxis, starting when released. Dilute 2 mL of famotidine with 8 mL of normal saline to a final concentration of 2 mg/mL. Administer ordered dose over a period of at least 2 minutes.
- Albuterol 90 mcg/puff inhaler 2 puff, Inhalation, ONCE PRN, Severe reaction p. Starting when released, For 1 dose. Shake well. Use with spacer.
- Start oxygen. For MODERATE Reaction: Start 2 liters O2 per nasal cannula as needed for SpO2 less than 93%. For SEVERE Reaction: Start continuous pulse oximetry. Administer 6 to 8 liters per minute (LPM) via face mask, or up to 100% oxygen to maintain oxygen saturation greater than 90%.
- EPINEPHrine 1 mg/mL injection 0.3 mg. Intramuscular, EVERY 5 MIN PRN, Anaphylaxis. Starting when released, For 3 doses. Administer in the anterior lateral thigh using 1 - 1.5-inch needle for airway obstruction symptoms and/or hypotension.
- Sodium chloride 0.9% (NS) infusion 500ml. At 500 mL/hr., Intravenous, PRN, Moderate reaction, or anaphylaxis. Starting when released. Run wide open to gravity.



3/2023

Ustekinumab (STELARA) INDUCTION Infusion only

NAME: **INSURANCE: PROVIDER NAME: CLINIC NAME and Phone number:**

Patient identification

By signing below, I represent the followin	ng:		
I am responsible for the care of the patien	t (who is identified at the top of this form).		
I hold an active, unrestricted license to pra	actice medicine in Oregon.		
My physician license Number is #	and I am acting within my scope of practice and		
	medications and blood products described above for the patient		
identified on this form.			
Durani da wa mainta di nama a			
Provider's printed name:			
Provider's signature: Date:			
Date.			
Please complete the following intake que	estions.		
Mobility status			
□ Independent			
□ Walker			
☐ Wheelchair	□ Wheelchair		
 Fully dependent 			
Bariatric needs			
Yes, briefly describe			
□ No			
Transportation concerns			
Yes, briefly describe			
□ No			
Interpreter Service required			
Yes, language			
□ No			
Outpatient Infusion Services Intake Team			
Please check the appropriate box for the	patient's preferred infusion center location:		
□ PORTLAND	Phone- 503-215-6046 Fax- 503-487-3582		
□ WILLAMETTE FALLS			
□ MEDFORD	Phone- 541-732-7000 Fax- 541-732-3939		
☐ HOOD RIVER	Phone- 541-387-6445 Call for fax #		
□ SEASIDE	Phone- 503-717-7650 Fax- 503-470-3146		
□ NEWBERG	Phone- 503-537-6040 Fax- 503-205-8720		